as used herein , the following terms have the meanings ascribed to them unless specified otherwise . in this disclosure , “ comprises ,” “ comprising ,” “ containing ” and “ having ” and the like can have the meaning ascribed to them in u . s . patent law and can mean “ includes ,” “ including ,” and the like ; “ consisting essentially of ” or “ consists essentially ” likewise has the meaning ascribed in u . s . patent law and the term is open - ended , allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited , but excludes prior art embodiments . the phrases “ oral bioavailability ” and “ bioavailability upon oral administration ” as used herein refer to the systemic availability ( i . e ., blood / plasma levels ) of a given amount of antibiotic administered to a patient . the term “ clearance ” as used herein refers to the removal of a substance from the blood , e . g ., by renal excretion , expressed in terms of the volume flow of blood or plasma that would contain the amount of substance removed per unit time . the term “ half - life ” as used herein refers to the period of time required for one - half of an amount of a substance to be lost through biological processes . the term “ bioavailability ” as used herein refers to the physiological availability of a given amount of a drug , as distinct from its chemical potency . the term may also refer to the proportion of the administered dose which is absorbed into the bloodstream . the term “ animal ” is used herein to include all vertebrate animals , including humans . it also includes an individual animal in all stages of development , including embryonic and fetal stages . as used herein , the term “ production animals ” is used interchangeably with “ livestock animals ” and refers generally to animals raised primarily for food . for example , such animals include , but are not limited to , cattle ( bovine ), sheep ( ovine ), pigs ( porcine or swine ), poultry ( avian ), and the like . as used herein , the term “ cow ” or “ cattle ” is used generally to refer to an animal of bovine origin of any age . interchangeable terms include “ bovine ”, “ calf ”, “ steer ”, “ bull ”, “ heifer ”, “ cow ” and the like . as used herein , the term “ pig ” is used generally to refer to an animal of porcine origin of any age . interchangeable terms include “ piglet ”, “ sow ” and the like . in a first embodiment , the present invention provides for a soft chewable veterinary formulation , which comprises an effective amount of therapeutic agent which comprises at least one antibiotic , a hydrophobic material , at least one filler , at least one disintegrant , at least one product containing flavor , at least one preservative , and at least one humectant . for soft chewable formulations , the antibiotic may be selected from the following , which is to be considered non - limiting : beta lactam , semisynthetic penicillins , bacitracin , cephalosporins , quinolones , fluorinated quinolones , polymyxin , tetracyclines , chloramphenicol , macrolides , aminoglycosides , nalidixic acid , rifamycins , and sulfonamides . some examples include amikacin , aminosalicyclic acid , amoxicillin , amoxicillin and clavulanate potassium , ampicillin , azithromycin , bacampicillin , bacitracin , capreomycin , carbenicillin , carbenicillin indanyl sodium , cefaclor , cefadroxil , cefaloridine , cefamandole , cefazolin , cefazolin sodium , cefepime , cefinetazole , cefixime , cefinetazole , cefodizime , cefonicid , cefoperazone , ceforanide , cefotaxime , cefotetan , cefoxitin , cefoxitin sodium , cefpirome , cefpodoxime , cefpodoxime proxetil , cefquinome , ceftaxidime , ceftibuten , ceftiofur , ceftizoxime , ceftriaxone , cefuroxime , cephacelor , cephadrine , cephalexin , cephalothin , cephamandole , cephapirin , cepharadine , cephprozil , chloramphenicol , chlortetracycline , ciprofloxacin , clarithromycin , clindamycin hcl , clindamycin or salts thereof , clindamycin phosphate , clofazimine , cloxacillin , colistin , co - triamoxazole , cycloserine , dalfopristin , danofloxacin , demeclocycline , dicloxacillin , difloxacin , dihydro - streptomycin , dirithromycin , docycycline , efrotomycin , enoxacin , enrofloxacin , ertapenem , erythromycin and salts thereof , ethambutol hcl and other salts , ethionamide , florfenicol , flumequine , fosfomycin , fosfomycin , gamithromycin , gatifloxacin , gentamycin , imipenem , imipenem - cilastin , isoniazid , kanamycin , levofloxacin , lincomycin , linezolid , lomefloxacin , loracarbef mafenide , marbofloxacin , meropenem , methenamine , methicillin , metronidazole , mezlocillin , minocycline , moxifloxacin , nafcillin , nalidixic acid , neomycin , netilmicin , nitrofurantoin , norfloxacin , novobiocin , ofloxacin , orbifloxacin , ormetoprim , oxacillin , oxytetracycline , paromomycin , penicillin g , penicillin g aqueous , penicillin g benzatine , penicillin g procaine , penicillin v , penicillin v penicillin salts and complexes , pentamidine , piperacillin , piperacillin sodium , piperacillin - tazobactam , polymixin b , pyrazinamide , rifampin , roxithromycin , salts of carbenicillin , silver sulfadiazine , sparfloxacin , spectinomycin , spiramycin , streptomycin , streptozocin , sufadimethoxine - ormetoprim , sulfacetamide , sulfacytine , sulfadiazine , sulfadimethoxine , sulfadimethoxine - trimethoprim , sulfamerazine , sulfamethazine , sulfamethixole , sulfapyridine , sulfapyrizine , sulfasalazine , sulfinethoxazole , sulfisoxazole , tazobactam , teicoplanin , tetracycline , tetracycline hcl , tiamulin , ticarcillin , ticarcillin and clavulanate potassium , tilmicosin , tobramycin , trimethoprim , trimetrexate and ketolides , troleanomycin , trovafloxacin , tulathromycin , tylosin , vancomycin and ketolides such as telithromycin and hmr 3004 . the amount of therapeutic agent depends on the individual therapeutic agent , the animal being treated , the disease state , and the severity of the disease state . the determination of those factors is well within the skill level of the practitioner . preferred formulations are those containing about 0 . 01 to 50 % w / w of therapeutic agent and especially preferred formulations are those containing about 2 . 5 to about 5 % w / w of therapeutic agent . advantageously , the soft chewable formulation contains as an antibiotic , clindamycin , or salts thereof . most preferred is clindamycin hcl in a range of 1 - 5 % w / w . for soft chewable formulations , the hydrophobic material may include surfactants of different degrees of hydrophobicity or hydrophilicity which can be prepared by reaction of alcohols or polyalcohols with a variety of natural and / or hydrogenated oils . most commonly , the oils used are castor oil or hydrogenated castor oil , or an edible vegetable oil such as corn oil , olive oil , peanut oil , palm kernel oil , apricot kernel oil , soybean oil , or almond oil . preferred alcohols include glycerol , propylene glycol , ethylene glycol , polyethylene glycol , sorbitol , and pentaerythritol . among these alcohol - oil transesterified surfactants , preferred hydrophilic surfactants are peg - 35 castor oil ( incrocas - 35 ), peg - 40 hydrogenated castor oil ( cremophor rh 40 ), peg - 25 trioleate ( tagat ® to ), peg - 60 corn glycerides ( crovol m70 ), peg - 60 almond oil ( crovol a70 ), peg - 40 palm kernel oil ( crovol pk70 ), peg - 50 castor oil ( emalex c - 50 ), peg - 50 hydrogenated castor oil ( emalex hc - 50 ), peg - 8 caprylic / capric glycerides ( labrasol ), and peg - 6 caprylic / capric glycerides ( softigen 767 ). preferred hydrophobic surfactants in this class include peg - 5 hydrogenated castor oil , peg - 7 hydrogenated castor oil , peg - 9 hydrogenated castor oil , peg - 6 corn oil ( labrafil ® m 2125 cs ), peg - 6 almond oil ( labrafil ® m 1966 cs ), peg - 6 apricot kernel oil ( labrafil ® m 1944 cs ), peg - 6 olive oil ( labrafil ® m 1980 cs ), peg - 6 peanut oil ( labrafil ® m 1969 cs ), peg - 6 hydrogenated palm kernel oil ( labrafil ® m 2130 bs ), peg - 6 palm kernel oil ( labrafil ® m 2130 cs ), peg - 6 triolein ( labrafil ® m 2735 cs ), peg - 8 corn oil ( labrafil ® wl 2609 bs ), peg - 20 corn glycerides ( crovol m40 ), and peg - 20 almond glycerides ( crovol a40 ). preferred formulations are those containing about 0 . 01 to 50 % w / w of hydrophobic material and especially preferred formulations are those containing about 1 to about 20 % w / w of hydrophobic material . advantageously , the soft chewable formulation contains as a hydrophobic material , hydrogenated vegetable oil . advantageously , the hydrogenated vegetable oil is present in the amounts of about 2 - 15 % based upon total weight of formulation . for soft chewable formulations , all fillers ( or diluents ) known in the soft chewable formulation art are contemplated . non - limiting examples of fillers include soy protein , corn cob , or corn glutton meal . preferred formulations are those containing about 5 to 80 % w / w of filler and especially preferred formulations are those containing about 10 to 70 % w / w of filler . advantageously , the soft chewable formulation contains as a filler , soy protein fines . advantageously , soy protein fines may be present in amounts of about 20 % to 60 % based upon total weight of formulation . for soft chewable formulations , flavors include those known in pet foods which are artificial and include , for example : a dry flavor formulated to provide the appeal of a baking a dry flavor formulated to provide the odor of fish meal . sources for these flavors are well - know to a practitioner in this art . for example , kermine petfood nutrisurance is a vegetarian flavor for pet food is sold by kemine industries , inc ., des moines , iw . a discussion of commercial smoke flavorings is provided by guillen et al . in j . agr . and food chemistry vol . 4 . preferred are the grillin &# 39 ; line of grill flavors and blends marketed by the red arrow products company , llc , manitowoc , wis . for human and pet food . these include grillin &# 39 ; type cb - 200 , grillin &# 39 ; type sd , grillin &# 39 ; type ws - 50 , grillin &# 39 ; type cn , grillin &# 39 ; type cb , grillin &# 39 ; type gs and grillin &# 39 ; type nbf . especially preferred are hickory smoked flavoring produced by combining torula yeast and an aqueous hickory smoke solution , sold by red arrow products co . as chartor hickory or a hickory smoke flavoring produced by combining maltodextin with an aqueous hickory smoke solution , sold by red arrow products co . as chardex hickory . other flavors contemplated by the invention include those which impart a natural dry smoke flavor . these include charzyme ( a smoke flavor produced by combining barley malt flour with an aqueous smoke flavor ), charmaize ( a smoke flavor produced by combining yellow flower and an aqueous smoke flavor ) and charsalt ( a blend of dendritic salt , aqueous smoke flavor , and hydrated silicon dioxide . all of these flavors may be obtained by red arrow products co . the determination of the amounts of flavor for a particular product is easily determined by a practitioner of this art . advantageously , the soft chewable formulation contains those flavors which provide a savory flavor . these flavors are well known to a practitioner of this art . typical ranges are from 5 - 30 % w / w . advantageously , the flavor is a hickory smoke flavor or a beef flavor . for soft chewable formulations , all preservatives known in the soft chewable formulation art are contemplated . non - limiting examples include the parabens ( methylparaben and / or propylparaben ), benzalkonium chloride , benzethonium chloride , benzoic acid , benzyl alcohol , bronopol , butylparaben , cetrimide , chlorhexidine , chlorobutanol , chlorocresol , cresol , ethylparaben , imidurea , methylparaben , phenol , phenoxyethanol , phenylethyl alcohol , phenylmercuric acetate , phenylmercuric borate , phenylmercuric nitrate , potassium sorbate , sodium benzoate , sodium propionate , sorbic acid , thimerosal , propyl paraben , myristyl gama - picolinium chloride , paraben methyl , paraben propyl and quaternary ammonium compounds and the like . preferred formulations are those containing about 0 . 05 to 5 % w / w of preservative and especially preferred formulations are those containing about 0 . 1 to 2 . 5 % w / w of preservative . advantageously , the preservative is methylparaben and / or propylparaben . advantageously , the preservative is suitably used in the formulation in amounts ranging from about 0 . 01 to about 2 . 0 % w / w , with about 0 . 2 to about 1 . 0 % w / w being especially preferred . for soft chewable formulations , all disintegrants known in the soft chewable formulation art are contemplated . non - limiting examples include sodium starch glycolate , crospovidone , croscarmellose sodium , starch , micocrystalline cellulose , alginic acid , veegum , crospovidone , bentonite , and pregelatinized starch . preferred formulations are those containing about 0 . 05 to 20 % w / w of disintegrant and especially preferred formulations are those containing about 1 to 12 % w / w of disintegrant . advantageously , the disintegrant is crospovidone . advantageously , the disintegrant is suitably used in the formulation in the amounts ranging from about 2 - 10 % w / w . for soft chewable formulations , all humectants known in the soft chewable formulation art are contemplated . non - limiting examples include propylene glycol , glycerin , polyethylene glycol 400 and polyethylene glycol 3350 . advantageously , the humectant is propylene glycol or purified water . advantageously , these humectants may be present in amounts of about 2 % to 20 % based upon total weight of formulation . the following chewable veterinary formulation is most preferred : clindamycin hcl between 1 and 10 %, hydrogenated vegetable oil is between 2 and 15 %, soy protein fines between 20 - 60 %, flavor between 5 - 30 %, preservative between 0 . 2 to 1 %, disintegrant between 2 and 10 %, and propylene glycol , purified water , and other ingredients between 2 and 20 %. optionally , the chewable veterinary formulations may also include lubricants , such as polyethylene glycols ( peg &# 39 ; s or carbowax ), corn oil , mineral oil , hydrogenated vegetable oils ( sterotex or lubritab ), peanut oil , magnesium stearate , soybean oil and / or castor oil . the inclusion and identity of a lubricant is readily determined by a practitioner of this art are present in amounts , for example , of about 0 . 01 to about 20 %, based upon total weight in the composition . absorbents may also be added to the chewable veterinary formulations . such compounds are well known in the art to the practitioner as well as their use in pastes . these compounds effectively prevent or alleviate the phase separation of the product during storage . preferred absorbents include magnesium carbonate , calcium carbonate , potassium bicarbonate , sodium bicarbonate , starch , cellulose and its derivatives , or mixtures of absorbents , with magnesium carbonate being especially preferred . the inclusion of these compounds is optional with amounts of 0 % to about 30 %, 0 to about 15 % or about 1 % to about 15 % or about 1 % to about 10 %, based on total weight of the formulation being especially preferred . antioxidants such as an alpha tocopheral , ascorbic acid , ascrobyl palmitate , fumeric acid , malic acid , sodium ascorbate , sodium metabisulfate , n - propyl gallate , bha ( butylated hydroxy anisole ), bht ( butylated hydroxy toluene ) monothioglycerol and the like , may be added to the present formulation . the antioxidants are generally added to the formulation in amounts of from about 0 . 01 to about 2 . 0 %, based upon total weight of the formulation , with about 0 . 1 to about 1 . 0 % being especially preferred . granulating solvents are well known to those skilled in this art . non - limiting examples of such solvents are water , aqueous sorbitol solution , etc . other compounds which can act as solvents include polyethylene glycol 3350 , glycerol caprylate / caprate and polyglycolized glycerides ( gelucire ). compounds which stabilize the ph of the formulation ( ph modifiers ) are also contemplated . again , such compounds are well known to a practitioner in the art as well as how to use these compounds . buffering systems include , for example , systems selected from the group consisting of acetic acid / acetate , malic acid / malate , citric acid / citrate , tataric acid / tartrate , lactic acid / lactate , phosphoric acid / phosphate , glycine / glycimate , tris , glutamic acid / glutamates and sodium carbonate . preferred ranges for ph include from about 4 to about 6 . 5 . other compounds contemplated by the inventive formulations include complexing agents , such as cyclodextrins , pvp , peg , ethyl lactate and niacinamide . amounts of such compounds to be included in the inventive formulation are well known to a practitioner of the art . also contemplated are therapeutic agents to be in the form of emulsions , liposomes or micelles . flow aids or glidants are also well known in the art and include , for example , silicon dioxide ( carbosil ) or silica gel ( syloid ), talc , starch , calcium , stearate , magnesium stearate , and aluminum magnesium silicate ( neusilin ). amounts of flow aids are readily determined by a practitioner in this art and include for using about 0 . 01 to about 25 %, based upon weight of total composition . non - limiting examples of lubricants for the tablets include magnesium and calcium stearate and stearic acid . again , the various lubricants are well known to a practitioner of this art as well as the amounts of these compounds . ranges include from about 0 . 01 to about 20 % based upon the total weight of formulation . further , the present invention provides for a method for enhancing the palatability of an oral veterinary formulation , which comprises including in the formulation a flavor that is ‘ liked ’ by dogs . this invention further provides for a process for preparing a chewable veterinary formulation , which comprises the steps of : ( a ) blending the pharmaceutical agent , hydrophobic material , disintegrant , flavor ; ( b ) adding the water , preservative , and the humectant to the mixture from step ( a ) and mixing the mixture ; and ( c ) without drying , extruding the mixture . in a second embodiment , the present invention provides for a tablet veterinary formulation , which comprises an effective amount of therapeutic agent which comprises at least one antibiotic , at least one filler , at least one disintegrant , at least one binder , at least one product containing flavor , at least one colorant , and at least one granulating solvent . for tablet formulations , the antibiotic may be selected from the following , which is to be considered non - limiting : beta lactam , semisynthetic penicillins , bacitracin , cephalosporins , quinolones , fluorinated quinolones , polymyxin , tetracyclines , chloramphenicol , macrolides , aminoglycosides , nalidixic acid , rifamycins , and sulfonamides . some examples include amikacin , aminosalicyclic acid , amoxicillin , amoxicillin and clavulanate potassium , ampicillin , azithromycin , bacampicillin , bacitracin , capreomycin , carbenicillin , carbenicillin indanyl sodium , cefaclor , cefadroxil , cefaloridine , cefamandole , cefazolin , cefazolin sodium , cefepime , cefinetazole , cefixime , cefinetazole , cefodizime , cefonicid , cefoperazone , ceforanide , cefotaxime , cefotetan , cefoxitin , cefoxitin sodium , cefpirome , cefpodoxime , cefpodoxime proxetil , cefquinome , ceftaxidime , ceftibuten , ceftiofur , ceftizoxime , ceftriaxone , cefuroxime , cephacelor , cephadrine , cephalexin , cephalothin , cephamandole , cephapirin , cepharadine , cephprozil , chloramphenicol , chlortetracycline , ciprofloxacin , clarithromycin , clindamycin hcl , clindamycin or salts thereof , clindamycin phosphate , clofazimine , cloxacillin , colistin , co - triamoxazole , cycloserine , dalfopristin , danofloxacin , demeclocycline , dicloxacillin , difloxacin , dihydro - streptomycin , dirithromycin , docycycline , efrotomycin , enoxacin , enrofloxacin , ertapenem , erythromycin and salts thereof , ethambutol hcl and other salts , ethionamide , florfenicol , flumequine , fosfomycin , fosfomycin , gamithromycin , gatifloxacin , gentamycin , imipenem , imipenem - cilastin , isoniazid , kanamycin , levofloxacin , lincomycin , linezolid , lomefloxacin , loracarbef mafenide , marbofloxacin , meropenem , methenamine , methicillin , metronidazole , mezlocillin , minocycline , moxifloxacin , nafcillin , nalidixic acid , neomycin , netilmicin , nitrofurantoin , norfloxacin , novobiocin , ofloxacin , orbifloxacin , ormetoprim , oxacillin , oxytetracycline , paromomycin , penicillin g , penicillin g aqueous , penicillin g benzatine , penicillin g procaine , penicillin v , penicillin v penicillin salts and complexes , pentamidine , piperacillin , piperacillin sodium , piperacillin - tazobactam , polymixin b , pyrazinamide , rifampin , roxithromycin , salts of carbenicillin , silver sulfadiazine , sparfloxacin , spectinomycin , spiramycin , streptomycin , streptozocin , sufadimethoxine - ormetoprim , sulfacetamide , sulfacytine , sulfadiazine , sulfadimethoxine , sulfadimethoxine - trimethoprim , sulfamerazine , sulfamethazine , sulfamethixole , sulfapyridine , sulfapyrizine , sulfasalazine , sulfinethoxazole , sulfisoxazole , tazobactam , teicoplanin , tetracycline , tetracycline hcl , tiamulin , ticarcillin , ticarcillin and clavulanate potassium , tilmicosin , tobramycin , trimethoprim , trimetrexate and ketolides , troleanomycin , trovafloxacin , tulathromycin , tylosin , vancomycin and ketolides such as telithromycin and hmr 3004 . preferred formulations are those containing about 0 . 01 to 50 % w / w of therapeutic agent and especially preferred formulations are those containing about 2 to about 20 % w / w of therapeutic agent . advantageously , the tablet formulation contains clindamycin , or salts thereof . most preferred is clindamycin hcl in a range of 4 - 15 % w / w . for tablet formulations , all fillers ( or diluents ) known in the tablet art are contemplated . non - limiting examples of fillers include anhydrous lactose , hydrated lactose , sprayed dried lactose , crystalline maltose and maltodextrins . advantageously , the tablet formulation contains as a filler , lactose . advantageously , the lactose may be present in amounts of about 40 % to 80 % based upon total weight of formulation . advantageously , the tablet formulation contains as a diluent , binder , carrier , filler , or as a flow enhancer , mannitol in a range of 5 - 15 % w / w . for tablet formulations , all binders known in the tablet art are contemplated . non - limiting examples of binders include polyvinyl pyrrolidone , povidone , starch , pregelatinized starch , gelatin , methylcellulose , hydroxypropyl cellulose , carboxymethyl cellulose sodium , ethylcellulose , sodium alginate , tragacanth , and acacia . preferred formulations are those containing about 1 to 20 % w / w of binder and especially preferred formulations are those containing about 2 - 12 % w / w of binder . advantageously , the binder may be present in amounts of about 3 - 10 % w / w , depending on the selection , and the amount , of disintegrant . for tablet formulations , all disintegrants known in the tablet art are contemplated . non - limiting examples of disintegrants include sodium starch glycolate , crospovidone , croscarmellose sodium , starch , micocrystalline cellulose , alginic acid , veegum , crospovidone , bentonite , and pregelatinized starch . preferred formulations are those containing about 1 to 20 % w / w of disintegrant and especially preferred formulations are those containing about 2 - 12 % w / w of disintegrant . advantageously , the disintegrant may be present in amounts of about 3 - 10 % w / w , depending on the selection , and therefore the amount , of binder . for tablet formulations , all flavors known in pet foods , which are artificial , are contemplated and include , for example : a dry flavor formulated to provide the appeal of a baking a dry flavor formulated to provide the odor of fish meal . sources for these flavors are well - know to a practitioner in this art . for example , kermine petfood nutrisurance is a vegetarian flavor for pet food is sold by kemine industries , inc ., des moines , iw . a discussion of commercial smoke flavorings is provided by guillen et al . in j . agr . and food chemistry vol . 4 . preferred are the grillin &# 39 ; line of grill flavors and blends marketed by the red arrow products company , llc , manitowoc , wis . for human and pet food . these include grillin &# 39 ; type cb - 200 , grillin &# 39 ; type sd , grillin &# 39 ; type ws - 50 , grillin &# 39 ; type cn , grillin &# 39 ; type cb , grillin &# 39 ; type gs and grillin &# 39 ; type nbf . especially preferred are hickory smoked flavoring produced by combining torula yeast and an aqueous hickory smoke solution , sold by red arrow products co . as chartor hickory or a hickory smoke flavoring produced by combining maltodextin with an aqueous hickory smoke solution , sold by red arrow products co . as chardex hickory . other flavors contemplated by the invention include those which impart a natural dry smoke flavor . these include charzyme ( a smoke flavor produced by combining barley malt flour with an aqueous smoke flavor ), charmaize ( a smoke flavor produced by combining yellow flower and an aqueous smoke flavor ) and charsalt ( a blend of dendritic salt , aqueous smoke flavor , and hydrated silicon dioxide . all of these flavors may be obtained by red arrow products co . the determination of the amounts of flavor for a particular product is easily determined by a practitioner of this art . preferred are those flavors which provide a savory flavor . these flavors are well known to a practitioner of this art . advantageously , the tablet formulation contains those flavors which provide a savory flavor . these flavors are well known to a practitioner of this art . typical ranges are from 5 - 30 % w / w . advantageously , the tablet formulation contains a hickory smoke flavor or a beef flavor . advantageously , flavor is added between 10 and 20 % based upon total weight of formulation . for tablet formulations , all colorants known in the tablet art are contemplated . non - limiting examples include , but are not limited to , dyes , an aluminum lake , caramel ( which may also function as a flavor ), colorant based upon iron oxide or a mixture of any of the foregoing . especially preferred are organic dyes and titanium dioxide . preferred ranges include from about 0 . 5 % to about 25 % based upon total weight of formulation . the following tablet formulation is most preferred : clindamycin hcl between 4 and 15 %, lactose carrier between 40 and 80 %, mannitol between 5 and 15 %, binder and disintegrant between 3 and 10 %, flavor between 10 and 20 %, color between 0 . 1 and 0 . 5 %, and purified water and other ingredients q . s . 100 %. optionally , the tablet formulations of the present invention may further contain other inert ingredients such as absorbents , antioxidants , granulating solvents , stabilizers or surfactants . these compounds are well known in the formulation art . absorbents may also be added to the inventive formulations . such compounds are well known in the art to the practitioner as well as their use in pastes . these compounds effectively prevent or alleviate the phase separation of the product during storage . preferred absorbents include magnesium carbonate , calcium carbonate , potassium bicarbonate , sodium bicarbonate , starch , cellulose and its derivatives , or mixtures of absorbents , with magnesium carbonate being especially preferred . the inclusion of these compounds is optional with amounts of 0 % to about 30 %, 0 to about 15 % or about 1 % to about 15 % or about 1 % to about 10 %, based on total weight of the formulation being especially preferred . antioxidants such as an alpha tocopheral , ascorbic acid , ascrobyl palmitate , fumeric acid , malic acid , sodium ascorbate , sodium metabisulfate , n - propyl gallate , bha ( butylated hydroxy anisole ), bht ( butylated hydroxy toluene ) monothioglycerol and the like , may be added to the present formulation . the antioxidants are generally added to the formulation in amounts of from about 0 . 01 to about 2 . 0 % w / w , with about 0 . 1 to about 1 . 0 % w / w being especially preferred . granulating solvents are well known to those skilled in this art . non - limiting examples of such solvents are water , aqueous sorbitol solution , etc . other compounds which can act as solvents include polyethylene glycol 3350 , glycerol caprylate / caprate and polyglycolized glycerides ( gelucire ). compounds which stabilize the ph of the formulation ( ph modifiers ) are also contemplated . again , such compounds are well known to a practitioner in the art as well as how to use these compounds . buffering systems include , for example , systems selected from the group consisting of acetic acid / acetate , malic acid / malate , citric acid / citrate , tataric acid / tartrate , lactic acid / lactate , phosphoric acid / phosphate , glycine / glycimate , tris , glutamic acid / glutamates and sodium carbonate . preferred ranges for ph include from about 4 to about 6 . 5 . other compounds contemplated by the inventive formulations include complexing agents , such as cyclodextrins , pvp , peg , ethyl lactate and niacinamide . amounts of such compounds to be included in the inventive formulation are well known to a practitioner of the art . also contemplated are therapeutic agents to be in the form of emulsions , liposomes or micelles . flow aids or glidants are also well known in the art and include , for example , silicon dioxide ( carbosil ) or silica gel ( syloid ), talc , starch , calcium , stearate , magnesium stearate , and aluminum magnesium silicate ( neusilin ). amounts of flow aids are readily determined by a practitioner in this art and include for using about 0 . 01 to about 25 %, based upon weight of total composition . non - limiting examples of lubricants for the tablets include magnesium and calcium stearate and stearic acid . again , the various lubricants are well known to a practitioner of this art as well as the amounts of these compounds . ranges include from about 0 . 01 to about 20 % based upon total weight of formulation . moreover , in an alternative embodiment this invention provides for tablets which are coated . the inventive tablets are prepared according to methods conventional in the art , such as wet and dry granulation processes . the chewable formulations and tablets provided for by this invention may be coated using techniques conventional in the art . coatings for chewables veterinary formulations include gelatin , glyceryl behenate , coca butter , and beeswax . other coatings would be known to a practitioner in this art . coatings for tablets include sugar coatings , such as seal coatings , subcoatings , and syrup coatings , as well as film coatings , such as pan - pour coatings and pan spray coatings . as well known to a practitioner of this art , the coatings contain additional components such as solvents , plasticizers , colorants , opaquant - extenders and film formers . often it is beneficial to administer a formulation that contains a combination of two or more antibiotics , which possess different activity , in order to obtain a composition with a broad spectrum of activity . the inventive oral formulations herein described may be used to co - administer more than one antibiotic . the inventive tablet formulations are prepared according to methods conventional in the art , such as wet and dry granulation processes . in a third embodiment , the present invention provides for a long - acting injectable ( lai ) formulation , which comprises at least one therapeutic agent which comprises at least one antibiotic , at least one polxamer , and at least one aqueous solvent . the antibiotic may be selected from the following , which is to be considered non - limiting : beta lactam , semisynthetic penicillins , bacitracin , cephalosporins , quinolones , fluorinated quinolones , polymyxin , tetracyclines , chloramphenicol , macrolides , aminoglycosides , nalidixic acid , rifamycins , and sulfonamides . some examples include amikacin , aminosalicyclic acid , amoxicillin , amoxicillin and clavulanate potassium , ampicillin , azithromycin , bacampicillin , bacitracin , capreomycin , carbenicillin , carbenicillin indanyl sodium , cefaclor , cefadroxil , cefaloridine , cefamandole , cefazolin , cefazolin sodium , cefepime , cefinetazole , cefixime , cefinetazole , cefodizime , cefonicid , cefoperazone , ceforanide , cefotaxime , cefotetan , cefoxitin , cefoxitin sodium , cefpirome , cefpodoxime , cefpodoxime proxetil , cefquinome , ceftaxidime , ceftibuten , ceftiofur , ceftizoxime , ceftriaxone , cefuroxime , cephacelor , cephadrine , cephalexin , cephalothin , cephamandole , cephapirin , cepharadine , cephprozil , chloramphenicol , chlortetracycline , ciprofloxacin , clarithromycin , clindamycin hcl , clindamycin or salts thereof , clindamycin phosphate , clofazimine , cloxacillin , colistin , co - triamoxazole , cycloserine , dalfopristin , danofloxacin , demeclocycline , dicloxacillin , difloxacin , dihydro - streptomycin , dirithromycin , docycycline , efrotomycin , enoxacin , enrofloxacin , ertapenem , erythromycin and salts thereof , ethambutol hcl and other salts , ethionamide , florfenicol , flumequine , fosfomycin , fosfomycin , gamithromycin , gatifloxacin , gentamycin , imipenem , imipenem - cilastin , isoniazid , kanamycin , levofloxacin , lincomycin , linezolid , lomefloxacin , loracarbef mafenide , marbofloxacin , meropenem , methenamine , methicillin , metronidazole , mezlocillin , minocycline , moxifloxacin , nafcillin , nalidixic acid , neomycin , netilmicin , nitrofurantoin , norfloxacin , novobiocin , ofloxacin , orbifloxacin , ormetoprim , oxacillin , oxytetracycline , paromomycin , penicillin g , penicillin g aqueous , penicillin g benzatine , penicillin g procaine , penicillin v , penicillin v penicillin salts and complexes , pentamidine , piperacillin , piperacillin sodium , piperacillin - tazobactam , polymixin b , pyrazinamide , rifampin , roxithromycin , salts of carbenicillin , silver sulfadiazine , sparfloxacin , spectinomycin , spiramycin , streptomycin , streptozocin , sufadimethoxine - ormetoprim , sulfacetamide , sulfacytine , sulfadiazine , sulfadimethoxine , sulfadimethoxine - trimethoprim , sulfamerazine , sulfamethazine , sulfamethixole , sulfapyridine , sulfapyrizine , sulfasalazine , sulfinethoxazole , sulfisoxazole , tazobactam , teicoplanin , tetracycline , tetracycline hcl , tiamulin , ticarcillin , ticarcillin and clavulanate potassium , tilmicosin , tobramycin , trimethoprim , trimetrexate and ketolides , troleanomycin , trovafloxacin , tulathromycin , tylosin , vancomycin and ketolides such as telithromycin and hmr 3004 . preferred formulations are those containing about 1 to 50 % w / v of therapeutic agent and especially preferred formulations are those containing about 8 to about 20 % w / v of therapeutic agent . advantageously , the long - acting injectable formulation contains clindamycin , or salts thereof . most preferred is clindamycin hcl in a range of 9 - 18 % w / v . the poloxamer may be selected from the following : . alpha .- hydro -. omega .- hydroxypoly ( oxyethylene ) poly ( oxypropylene ) poly ( oxyethylene ) block copolymer , 1 , 2 - propyleneglycol , ethoxylated and propoxylated , 106392 - 12 - 5 , 11104 - 97 - 5 , 53637 - 25 - 5 , 60407 - 69 - 4 , 65187 - 10 - 2 , 69070 - 95 - 7 , 75 - h - 1400 , 75h90000 , 9003 - 11 - 6 , adeka 25r1 , adeka 25r2 , adeka l 61 , adeka pluronic f 108 , aids - 162017 , aids162017 , alpha - hydro - omega - hydroxypoly ( oxyethylene )( sub a )- poly ( oxopropylene )( sub b )- poly ( oxyethylene )( sub a ) block copolymer , alpha - hydro - omega - hydroxypoly ( oxyethylene ) a - poly ( oxopropylene ) b - poly ( oxyethylene ) a block copolymer , antarox 17r4 , antarox 25r2 , antarox b 25 , antarox f 108 , antarox f 68 , antarox f 88 , antarox f 88fl , antarox l 61 , antarox l 72 , antarox p 104 , antarox p 84 , antarox sc 138 , arco polyol r 2633 , arcol e 351 , b 053 , basf - l 101 , berol tvm370 , bloat guard , block polyethylene - polypropylene glycol , block polyoxyethylene - polyoxypropylene , breox bl 19 - 10 , bsp 5000 , c13430 , cirrasol aln - ws , component of casakol , component of epitrate , crisvon assistor sd 14 , crl 1005 , crl 1605 , crl 8131 , crl 8142 , d 500 ( polyglycol ), daltocel f 460 , dehypon ke 3557 , detalan , eban 710 , emkalyx ep 64 , emkalyx l 101 , emkalyx l101 , empilan p 7068 , emulgen pp 230 , epan 450 , epan 485 , epan 710 , epan 750 , epan 785 , epan u 108 , epon 420 , ethylene glycol - propylene glycol block copolymer , ethylene glycol - propylene glycol polymer , ethylene oxide , propylene oxide block polymer , ethylene oxide - propylene oxide block copolymer dipropylene glycol ether , ethylene oxide - propylene oxide block copolymer ether with ethylene glycol , ethylene oxide - propylene oxide block polymer , ethylene oxide - propylene oxide copolymer , f 108 , f 127 , f 77 , f 87 , f 88 , f - 108 , genapol pf 10 , glycols , polyethylene - polypropylene , glycols , polyethylenepolypropylene , hsdb 7222 , hydrowet , laprol 1502 , lg 56 , lutrol f , lutrol f ( tn ), m 90 / 20 , magcyl , meroxapol 105 , methyloxirane polymer with oxirane block , methyloxirane - oxirane copolymer , methyloxirane - oxirane polymer , monolan 8000e80 , monolan pb , n 480 , newpol pe - 88 , niax 16 - 46 , niax lg 56 , nissan pronon 201 , nixolen sl 19 , nsc 63908 , nsc63908 , oligoether l - 1502 - 2 - 30 , oxirane , methyl -, polymer with oxirane , oxirane , methyl -, polymer with oxirane , block , oxirane , methyl -, polymer with oxirane , ether with 1 , 2 - propanediol ( 2 : 1 ), oxirane , polymer with methyloxirane , oxirane - methyloxirane polymer , p 103 , p 104 , p 105 , p 123 , p 65 , p 84 , p 85 , peg / ppg - 125 / 30 copolymer , plonon 201 , plonon 204 , pluracare , pluracol v , pluriol pe , pluriol pe 6810 , pluronic , pluronic 10r8 , pluronic 31r2 , pluronic c 121 , pluronic f , pluronic f 108 , pluronic f 125 , pluronic f 127 , pluronic f 38 , pluronic f 68 , pluronic f 68lf , pluronic f 87 , pluronic f 88 , pluronic f 98 , pluronic f - 68 , pluronic f108 , pluronic f127 , pluronic f68 , pluronic f77 , pluronic f86 , pluronic f87 , pluronic f87 - a7850 , pluronic f88 , pluronic l , pluronic l 101 , pluronic l 121 , pluronic l 122 , pluronic l 24 , pluronic l 31 , pluronic l 35 , pluronic l 44 , pluronic l 61 , pluronic l 62 , pluronic l 64 , pluronic l 68 , pluronic l 92 , pluronic l - 101 , pluronic l - 81 , pluronic 144 , pluronic l62 , pluronic 162 ( mw 2500 ), pluronic l64 , pluronic 164 ( mw 2900 ), pluronic p , pluronic p 104 , pluronic p 75 , pluronic p 85 , pluronic p - 65 , pluronic p - 75 , pluronic p103 , pluronic p104 , pluronic p105 , pluronic p123 , pluronic p65 , pluronic p84 , pluronic p85 , pluronic - 68 , poloxalene , poloxalene l64 , poloxalene [ usan : ban : inn ], poloxalkol , poloxamer , poloxamer 101 , poloxamer 108 , poloxamer 182lf , poloxamer 188 , poloxamer 331 , poloxamer 407 , poloxamer [ usan : ban : inn ], poloxamer - 188 , poly ( propylene oxide - ethylene oxide ), poly ( ethylene oxide - co - propylene oxide ), poly ( mixed ethylene , propylene ) glycol , poly ( oxyethylene )- poly ( oxypropylene ) glycol , poly ( oxyethylene )- poly ( oxypropylene ) polymer , polyethylene glycol , propoxylated , polyethylene oxide - polypropylene oxide , polyethylene oxide - polypropylene oxide copolymer , polyethylene - pluronic l - 62lf , polyethylene - polypropylene glycol , polykol , polylon 13 - 5 , polyoxamer 108 , polyoxyethylenated poly ( oxypropylene ), polyoxyethylene - polyoxypropylene block copolymer , polyoxyethylene - polyoxypropylene copolymer , polyoxyethylene polyoxypropylene , polyoxyethylene - oxy - propylene [ french ], polyoxyethylene - polyoxypropylene , polyoxyethylene - polyoxypropylene polymer , polyoxypropylene - polyoxyethylene block copolymer , polypropoxylated , polyethoxylated propylene glycol , polypropylene glycol , ethoxylated , polypropylene glycol - ethylene oxide copolymer , ppg diol 3000eo , proksanol , pronon , pronon102 , pronon104 , pronon201 , pronon204 , pronon 208 , propane - 1 , 2 - diol , ethoxylated , propoxylated , propylen m 12 , propylene glycol , propylene oxide , ethylene oxide polymer , propylene oxide - ethylene oxide copolymer , propylene oxide - ethylene oxide polymer , proxanol , proxanol 158 , proxanol 228 , proxanol tsl - 3 , rc 102 , regulaid , rokopol 16p , rokopol 30p , rokopol 30p9 , sk and f 18 , 667 , sk & amp ; f 18 , 667 , skandf 18 , 667 , slovanik , slovanik 630 , slovanik 660 , slovanik m - 640 , supronic b 75 , supronic e 400 , synperonic pe 30 / 40 , tergitol monionic xh , tergitol nonionic xh , tergitol xh , tergitol xh ( nonionic ), teric pe 61 , teric pe 62 , teric pe40 , teric pe60 , teric pe70 , thanol e 4003 , therabloat , tsl 431 , tvm 370 , unilube 50 mb168x , unilube 50 mb26x , velvetol oe 2nt1 , voranol p 2001 , ws 661 , wyandotte 7135 . preferred formulations are those containing about 1 to 50 % w / v of poloxamer and especially preferred formulations are those containing about 5 to about 40 % w / v of poloxamer . advantageously , the poloxamer is lutrol ® f 127 and lutrol ® f 68 and is suitably used in the formulation in the amounts ranging from about 10 - 30 % w / v . most preferred is a lai formulation , which comprises : clindamycin phosphate between 9 and 18 %, lutrol ® between 5 and 30 %, and sterile water for injection q . s . 100 %. the long - acting injectable formulation of the present invention may be prepared by adding the therapeutic agent with the poloxamer and mixing until uniform . since the long acting formulation is intended for injection , it is necessary that it be sterilized . heat sterilization is generally to be avoided in the situation where the therapeutic agent is unstable at autoclave temperatures . rather , membrane sterilization is preferred in those situations . the sterile mixture is further mixed with sterile water for injection , q . s . to 100 %. in an alternative embodiment , the long - acting injectable veterinary formulation comprises the steps of : ( a ) stirring the poloxamer into purified water at 5 ° c . ; ( b ) optionally adding a second poloxamer to the mixture from step ( a ) and mixing the mixture ; and ( c ) optionally adding a polyacrylic acid into an aliquot of water , and completely hydrating the polyacrylic acid before mixing it into the poloxamer solution at 5 ° c . ; ( d ) neutralizing the carbopol using triethanolamine . ( e ) dissolving the drug in ethanol / propylene glycol and adding it to the above solution . in an alternative embodiment , the long - acting injectable veterinary formulation comprises the steps of : ( a ) dissolving lutrol ® f 127 completely in water at room temperature or water pre - cooled to approximately 5 ° c . ( b ) dissolving active substances that are insoluble in water , in ethanol , isopropanol or propylene glycol ( c ) mixing the therapeutic agent solution with the aqueous phase at 5 ° c . to form a homogeneous mass . in an alternative embodiment , the long - acting injectable veterinary formulation comprises the steps of : ( a ) dissolving lutrol ® f 127 in water at room temperature at approximately 70 ° c . ( b ) dissolving active substances that are insoluble in water , in ethanol , isopropanol or propylene glycol at 70 ° c . ( c ) mixing the therapeutic agent solution with the warm aqueous phase to form a homogeneous mass . the inventive formulations herein described may be used to treat a number of disease states by administering to the host in need thereof an effective amount of the formulation containing the pharmaceutical agent . the determining of a treatment protocol of a specific indication would be well within the skill level of a practitioner in the pharmaceutical or veterinary arts . the hosts include all animals , e . g . cats , dogs , cattle , sheep , horses , and pigs . the inventive formulations herein described may be administered to a warm - blooded animals , such as cattle , sheep , pigs , cats , dogs , horses , llamas , deer , rabbits , skunks , raccoons , camels and the like , or birds . the amount of pharmaceutical active agent depends on the individual therapeutic agent , the animal being treated , the disease state , and the severity of the disease state . the determination of those factors is well within the skill level of the practitioner . tablet and soft chewable formulations demonstrate comparable bioavailability to a conventional capsule product six healthy beagle or mongrel dogs , 6 . 3 to 15 . 0 months of age , weighing 7 . 8 to 10 . 0 kg were studied in this randomized , five - period crossover study . dogs were randomly assigned to one of three treatment sequences by lottery . within each sequence , dogs received one of three treatments on days 0 , 7 , 14 , 21 and 28 . on each treatment day , dogs received either clindamycin capsules ( group 1 ), soft chewables ( group 2 ) or chewable tablets ( group 3 ). all treatments were administered orally at a dose rate of at least 10 mg / kg . blood samples were collected prior to each treatment and at 0 . 5 , 1 , 1 . 5 , 3 , 6 , 12 and 24 hours after each treatment . fig1 provides plasma concentration levels ( ng / ml ) of clindamycin at each time point . the results indicate that the mean concentration - time profiles were parallel , with the mean cmax slightly higher for the commercial product , antirobe . the pharmacokinetic parameters among the three treatment groups were similar with average terminal half lives of 5 - 7 hr and average times to maximum concentration of 1 . 1 - 1 . 6 hr . the relative bioavailabilities of the soft and hard chews are 87 and 110 % w / v , respectively compared to antirobe . additionally , the pharmacokinetic parameters were broadly similar between groups fed 1 . 5 - 3 hour post dose versus 6 hours post dose for all formulations . a bioanalytical method for the determination of clindamycin from canine serum samples was developed using reversed - phase hplc with uv detection . all serum samples were extracted using a liquid - liquid extraction procedure and injected on an hplc with uv absorption at 210 nm . sets of fortified control samples to assess method performance , along with an unfortified control sample were included to assess any inherent interference . pharmacokinetic analysis was performed using winnonlin software , version 4 . 0 ( pharsight corporation , mountain view , calif ., 2002 ). the area under the plasma concentration - time curve ( auc ) was calculated using the linear / logarithmic trapezoidal method from 0 to the last point at which drug concentration was quantified [ auc ( 0 - t last )]. clearance and volume of distribution values , not corrected for bioavailability , were also calculated for each animal . the terminal elimination half life was calculated via linear regression of the last two to four nonzero values . c max and t max for each animal were taken as the highest observed concentration and time to that observation . various kinds of lutrol ® are available for use in the lai formulation . in the present example , preferred poloxamers were lutrol ® f 127 ( poloxamer 407 ) and f 68 ( poloxamer 188 ). lutrol ® f 127 is soluble in water , ethanol ( 95 %) and isopropanol . it is used primarily as a thickening agent and gel former . in particular , lutrol ® f 127 is suitable for the formulation of active substances that show reduced solubility as a result of neutralization . owing to its ability to affect viscosity , lutrol ® f 127 is suitable as a stabilizer for topically and orally administered suspensions . lutrol ® f 68 is readily soluble in water . it is primarily applied as an emulsifier , solubilizer , and suspension stabilizer in liquid oral , topical and parenteral dosage forms . it is particularly useful for enhancing the solubility and bioavailability of sparingly water soluble active drugs . lutrol ® f 68 has a low toxicity profile with minimal side effects . in the present example , lutrol ® f 127 and f 68 may be used in combination . when lutrol ® f 68 is used in combination with a gel - forming poloxamer , like lutrol ® f 127 , it strongly influences the thermorheological properties of f127 preparations , resulting in an increase of the sol - gel transition temperature . at constant amounts of f 127 , the viscosity and thermo - reversible gelling temperature are functions of the lutrol ® f 68 concentration . lutrol ® f 127 will be stirred into purified water at 5 ° c . and lutrol ® f 68 will be added . for the bioadhesive formulations , a polyacrylic acid ( paa ) will be dispersed into an aliquot of water , completely hydrated , and mixed with the lutrol ® solution at 5 ° c . the carbopol will be neutralized using triethanolamine . the drug will be dissolved in ethanol / propylene glycol and the solution added . lutrol ® f 127 will be dissolved completely in water at room temperature or water pre - cooled to approximately 5 ° c . active substances that are insoluble in water will be dissolved in ethanol , isopropanol or propylene glycol and mixed with the aqueous phase at 5 ° c . to form a homogeneous mass . lutrol ® f 127 will be dissolved in water at approximately 70 ° c . active substances that are insoluble in water will be dissolved in ethanol , isopropanol or propylene glycol at 70 ° c . and mixed with the warm aqueous phase to form a homogeneous mass . the gel will form when the solution cools to room temperature . rheology : using a rotation viscosimeter equipped with a probe the thermorheological behavior will be measured by adjusting a temperature interval from 0 - 90 ° c . with a ramp of 1 ° c . per minute . the rotation speed will be kept constant at 250 rpm . the rheological studies will be examined at a temperature of 40 ° c . using a shear rate from 0 - 65 - 0 rpm within 120 s . gel strength : the resistance to penetration of the gels at 40 ° c . will be performed by means of a software - controlled penetrometer with a 5 kg load cell and a 20 mm probe . the pre - test speed will be adjusted at 5 mm / s and the test speed will be 1 mm / s . the chosen penetration depth will be 5 mm . thermorheological properties : the addition of lutrol ® f 68 is expected to strongly influence the thermorheological properties of f 127 formulations . in contrast to the effect of common used salts ( e . g . nacl ) the addition of lutrol ® f 68 to lutrol ® f 127 formulations is expected to result in an increase of the sol - gel - transition temperature . at constant amounts of lutrol ® f 68 the thermoreversible gelling temperature can be adjusted by varying the lutrol ® f 127 concentration . the addition of small amounts of paa as bioadhesive polymer is expected to lead to a further decrease of the gelling temperature of the lutrol ® f 127 / f 68 combinations . viscosity : a considerable increase of the viscosity is expected to be observed with rising amounts of lutrol ® f 68 . at high concentrations of lutrol ® f 68 a sharp gelling temperature and a strong viscosity increase is expected . the viscosity of the gel form is expected to be higher when small quantities of paa are present . with increasing amount of paa these effects are expected to be reinforced . the influence of the different f 127 / f 68 combinations and the addition of paa on the viscosity of the gels will be confirmed by penetration resistance measurements . therapeutic agent : the choice of therapeutic agent is expected to strongly influence the properties of the lutrol ® f 127 / f 68 mixtures by lowering the gelling temperature . the required amount of lutrol f 127 will have to be adapted . the viscosity of lutrol f 127 gels may be affected by the addition of electrolytes , moisturizers , alcohols and surfactants . thus , the addition of more than 1 % sodium chloride will reduce the gel formation temperature as well as the viscosity and pour point . similar effects are also seen with potassium chloride . in contrast to this , ethanol will increase the gel formation temperature . the use of anionic surfactants may inhibit gel formation , even at lutrol f 127 concentrations of over 20 %. this is true , for example , for sodium lauryl sulphate at concentrations above 2 %. low ph values affect both the gel formation temperature and the viscosity . 1 . a chewable antibiotic formulation comprising an antibiotic , hydrophobic material , a filler , a disintegrant , a solvent , and optionally a flavor , and optionally a preservative . 2 . the formulation according to paragraph 1 wherein the antibiotic is between 1 and 5 % of the formulation , the hydrophobic material is between 2 and 15 %, the filler is between 20 - 60 %, the flavor is between 5 - 30 %, the preservative is between 0 . 2 to 1 %, the disintegrant is between 2 and 10 %, and the humectant is between 2 and 20 %. 3 . the formulation according to paragraph 2 wherein the antibiotic is selected from the group consisting of amikacin , aminosalicyclic acid , amoxicillin , amoxicillin and clavulanate potassium , ampicillin , azithromycin , bacampicillin , bacitracin , capreomycin , carbenicillin , carbenicillin indanyl sodium , cefaclor , cefadroxil , cefaloridine , cefamandole , cefazolin , cefazolin sodium , cefepime , cefinetazole , cefixime , cefinetazole , cefodizime , cefonicid , cefoperazone , ceforanide , cefotaxime , cefotetan , cefoxitin , cefoxitin sodium , cefpirome , cefpodoxime , cefpodoxime proxetil , cefquinome , ceftaxidime , ceftibuten , ceftiofur , ceftizoxime , ceftriaxone , cefuroxime , cephacelor , cephadrine , cephalexin , cephalothin , cephamandole , cephapirin , cepharadine , cephprozil , chloramphenicol , chlortetracycline , ciprofloxacin , clarithromycin , clindamycin hcl , clindamycin or salts thereof , clindamycin phosphate , clofazimine , cloxacillin , colistin , co - triamoxazole , cycloserine , dalfopristin , danofloxacin , demeclocycline , dicloxacillin , difloxacin , dihydro - streptomycin , dirithromycin , docycycline , efrotomycin , enoxacin , enrofloxacin , ertapenem , erythromycin and salts thereof , ethambutol hcl and other salts , ethionamide , florfenicol , flumequine , fosfomycin , fosfomycin , gamithromycin , gatifloxacin , gentamycin , imipenem , imipenem - cilastin , isoniazid , kanamycin , levofloxacin , lincomycin , linezolid , lomefloxacin , loracarbef mafenide , marbofloxacin , meropenem , methenamine , methicillin , metronidazole , mezlocillin , minocycline , moxifloxacin , nafcillin , nalidixic acid , neomycin , netilmicin , nitrofurantoin , norfloxacin , novobiocin , ofloxacin , orbifloxacin , ormetoprim , oxacillin , oxytetracycline , paromomycin , penicillin g , penicillin g aqueous , penicillin g benzatine , penicillin g procaine , penicillin v , penicillin v penicillin salts and complexes , pentamidine , piperacillin , piperacillin sodium , piperacillin - tazobactam , polymixin b , pyrazinamide , rifampin , roxithromycin , salts of carbenicillin , silver sulfadiazine , sparfloxacin , spectinomycin , spiramycin , streptomycin , streptozocin , sufadimethoxine - ormetoprim , sulfacetamide , sulfacytine , sulfadiazine , sulfadimethoxine , sulfadimethoxine - trimethoprim , sulfamerazine , sulfamethazine , sulfamethixole , sulfapyridine , sulfapyrizine , sulfasalazine , sulfinethoxazole , sulfisoxazole , tazobactam , teicoplanin , tetracycline , tetracycline hcl , tiamulin , ticarcillin , ticarcillin and clavulanate potassium , tilmicosin , tobramycin , trimethoprim , trimetrexate and ketolides , troleanomycin , trovafloxacin , tulathromycin , tylosin , vancomycin and ketolides such as telithromycin and hmr 3004 . 4 . the formulation according to paragraph 2 wherein the antibiotic is clindamycin or a pharmaceutically acceptable salt or hydrate thereof . 5 . the formulation according to paragraph 2 wherein the hydrophobic material is selected from the group consisting of glyceryl behenate , hydrogenated vegetable oil , stearic acid , glyceryl monostearate , glycerylpalmito stearate or cetyl alcohol . 6 . the formulation according to paragraph 2 wherein the hydrophobic material is hydrogenated vegetable oil . 7 . the formulation according to paragraph 2 where in the filler is selected from the group consisting of soy protein , corn cob , or corn glutton meal . 8 . the formulation according to paragraph 2 where in the filler is soy protein . 9 . the formulation according to paragraph 2 wherein the flavor is a hickory smoke flavor or a beef flavor . 10 . the formulation according to paragraph 2 wherein the preservative is selected from the group consisting of parabens ( methylparaben and / or propylparaben ), benzalkonium chloride , benzethonium chloride , benzoic acid , benzyl alcohol , bronopol , butylparaben , cetrimide , chlorhexidine , chlorobutanol , chlorocresol , cresol , ethylparaben , imidurea , methylparaben , phenol , phenoxyethanol , phenylethyl alcohol , phenylmercuric acetate , phenylmercuric borate , phenylmercuric nitrate , potassium sorbate , sodium benzoate , sodium propionate , sorbic acid , thimerosal , propyl paraben , myristyl gama - picolinium chloride , paraben methyl , paraben propyl and quaternary ammonium compounds . 11 . the formulation according to paragraph 2 wherein the preservative is methylparaben and / or propylparaben . 12 . the formulation according to paragraph 2 wherein the disintegrant is selected from the group consisting of sodium starch glycolate , crospovidone , croscarmellose sodium , starch , micocrystalline cellulose , alginic acid , veegum , crospovidone , bentonite , and pregelatinized starch . 13 . the formulation according to paragraph 2 wherein the disintegrant is crospovidone . 14 . the formulation according to paragraph 2 wherein the humectant is selected from the group consisting of propylene glycol , glycerin , polyethylene glycol 400 and polyethylene glycol 3350 . 15 . the formulation according to paragraph 2 wherein the humectant is propylene glycol or purified water . 16 . a process for preparing a chewable veterinary formulation according to paragraph 1 which comprises the steps of : ( a ) blending the pharmaceutical agent , hydrophobic material , disintegrant , flavor ; ( b ) adding the water , preservative , and the humectant to the mixture from step ( a ) and mixing the mixture ; and ( c ) without drying , extruding the mixture . 17 . a method of achieving bioavailability in an animal of a therapeutic agent that is comparable to commercially available products , comprising administering to an animal any one of the formulations of paragraphs 1 through 15 . 18 . a method for treating a bacterial infection in an animal comprising administering to the animal any one of the formulations of paragraphs 1 through 15 . 19 . the method of paragraph 18 wherein the animal receives treatment on days 0 , 7 , 14 , 21 , and 28 comprising administering any of the formulations of paragraphs 1 through 15 . 20 . an antibiotic formulation comprising an antibiotic , a lactose carrier , a filler , a binder and disintegrant , an aqueous solvent , and optionally a flavor , and optionally color . 21 . the formulation according to paragraph 20 wherein the antibiotic is between 4 and 15 %, the lactose carrier is between 40 and 80 %, mannitol is between 5 and 15 %, the binder and disintegrant are between 3 and 10 %, the flavor is between 10 and 20 %, the color is between 0 . 1 and 0 . 5 %, and the aqueous solvent is of a concentration sufficient to q . s . to 100 %. 22 . the formulation according to paragraph 21 wherein the antibiotic is selected from the group consisting of amikacin , aminosalicyclic acid , amoxicillin , amoxicillin and clavulanate potassium , ampicillin , azithromycin , bacampicillin , bacitracin , capreomycin , carbenicillin , carbenicillin indanyl sodium , cefaclor , cefadroxil , cefaloridine , cefamandole , cefazolin , cefazolin sodium , cefepime , cefinetazole , cefixime , cefinetazole , cefodizime , cefonicid , cefoperazone , ceforanide , cefotaxime , cefotetan , cefoxitin , cefoxitin sodium , cefpirome , cefpodoxime , cefpodoxime proxetil , cefquinome , ceftaxidime , ceftibuten , ceftiofur , ceftizoxime , ceftriaxone , cefuroxime , cephacelor , cephadrine , cephalexin , cephalothin , cephamandole , cephapirin , cepharadine , cephprozil , chloramphenicol , chlortetracycline , ciprofloxacin , clarithromycin , clindamycin hcl , clindamycin or salts thereof , clindamycin phosphate , clofazimine , cloxacillin , colistin , co - triamoxazole , cycloserine , dalfopristin , danofloxacin , demeclocycline , dicloxacillin , difloxacin , dihydro - streptomycin , dirithromycin , docycycline , efrotomycin , enoxacin , enrofloxacin , ertapenem , erythromycin and salts thereof , ethambutol hcl and other salts , ethionamide , florfenicol , flumequine , fosfomycin , fosfomycin , gamithromycin , gatifloxacin , gentamycin , imipenem , imipenem - cilastin , isoniazid , kanamycin , levofloxacin , lincomycin , linezolid , lomefloxacin , loracarbef mafenide , marbofloxacin , meropenem , methenamine , methicillin , metronidazole , mezlocillin , minocycline , moxifloxacin , nafcillin , nalidixic acid , neomycin , netilmicin , nitrofurantoin , norfloxacin , novobiocin , ofloxacin , orbifloxacin , ormetoprim , oxacillin , oxytetracycline , paromomycin , penicillin g , penicillin g aqueous , penicillin g benzatine , penicillin g procaine , penicillin v , penicillin v penicillin salts and complexes , pentamidine , piperacillin , piperacillin sodium , piperacillin - tazobactam , polymixin b , pyrazinamide , rifampin , roxithromycin , salts of carbenicillin , silver sulfadiazine , sparfloxacin , spectinomycin , spiramycin , streptomycin , streptozocin , sufadimethoxine - ormetoprim , sulfacetamide , sulfacytine , sulfadiazine , sulfadimethoxine , sulfadimethoxine - trimethoprim , sulfamerazine , sulfamethazine , sulfamethixole , sulfapyridine , sulfapyrizine , sulfasalazine , sulfinethoxazole , sulfisoxazole , tazobactam , teicoplanin , tetracycline , tetracycline hcl , tiamulin , ticarcillin , ticarcillin and clavulanate potassium , tilmicosin , tobramycin , trimethoprim , trimetrexate and ketolides , troleanomycin , trovafloxacin , tulathromycin , tylosin , vancomycin and ketolides such as telithromycin and hmr 3004 . 23 . the formulation according to paragraph 21 wherein the antibiotic is clindamycin or a pharmaceutically acceptable salt or hydrate thereof . 24 . the formulation according to paragraph 21 wherein the antibiotic is clindamycin hcl . 25 . the formulation according to paragraph 21 wherein the filler is selected from the group consisting of anhydrous lactose , hydrated lactose , sprayed dried lactose , crystalline maltose and maltodextrins . 26 . the formulation according to paragraph 21 wherein the filler is lactose . 27 . the formulation according to paragraph 21 wherein the binder is selected from the group consisting of polyvinyl pyrrolidone , povidone , starch , pregelatinized starch , gelatin , methylcellulose , hydroxypropyl cellulose , carboxymethyl cellulose sodium , ethylcellulose , sodium alginate , tragacanth , and acacia . 28 . the formulation according to paragraph 21 wherein the binder is polyvinyl pyrrolidone . 29 . the formulation according to paragraph 21 wherein the disintegrant is selected from the group consisting of sodium starch glycolate , crospovid one , croscarmellose sodium , starch , micocrystalline cellulose , alginic acid , veegum , crospovidone , bentonite , and pregelatinized starch . 30 . the formulation according to paragraph 21 wherein the disintegrant is crospovidone . 31 . the formulation according to paragraph 21 wherein the flavor is a hickory smoke flavor or a beef flavor . 32 . the formulation according to paragraph 21 wherein the colorant is selected from the group consisting of dyes , an aluminum lake , caramel , colorant based upon iron oxide or a mixture of any of the foregoing . 33 . the formulation according to paragraph 21 wherein the colorant is selected from the group consisting of organic dyes and titanium dioxide . 34 . a process for preparing the chewable veterinary formulation according to paragraph 20 which comprises mixing the ingredients intimately and pressing into single scored tablets . 35 . a method of achieving bioavailability in an animal of a therapeutic agent that is comparable to commercially available products , comprising administering to an animal any one of the formulations of paragraphs 20 through 33 . 36 . a method for treating a bacterial infection in an animal comprising administering to the animal any one of the formulations of paragraphs 20 through 33 . 37 . the method of paragraph 36 wherein the animal receives treatment on days 0 , 7 , 14 , 21 , and 28 comprising administering any of the formulations of paragraphs 20 through 33 . 38 . a long - acting injectable veterinary formulation comprising an antibiotic , a poloxamer , and sterile water for injection . 39 . the formulation according to paragraph 38 wherein the antibiotic is between 9 and 18 %, the poloxamer is between 5 and 30 %, and sterile water for injection is of a concentration sufficient to q . s . to 100 %. 40 . the formulation according to paragraph 39 wherein the antibiotic is selected from the group consisting of amikacin , aminosalicyclic acid , amoxicillin , amoxicillin and clavulanate potassium , ampicillin , azithromycin , bacampicillin , bacitracin , capreomycin , carbenicillin , carbenicillin indanyl sodium , cefaclor , cefadroxil , cefaloridine , cefamandole , cefazolin , cefazolin sodium , cefepime , cefinetazole , cefixime , cefinetazole , cefodizime , cefonicid , cefoperazone , ceforanide , cefotaxime , cefotetan , cefoxitin , cefoxitin sodium , cefpirome , cefpodoxime , cefpodoxime proxetil , cefquinome , ceftaxidime , ceftibuten , ceftiofur , ceftizoxime , ceftriaxone , cefuroxime , cephacelor , cephadrine , cephalexin , cephalothin , cephamandole , cephapirin , cepharadine , cephprozil , chloramphenicol , chlortetracycline , ciprofloxacin , clarithromycin , clindamycin hcl , clindamycin or salts thereof , clindamycin phosphate , clofazimine , cloxacillin , colistin , co - triamoxazole , cycloserine , dalfopristin , danofloxacin , demeclocycline , dicloxacillin , difloxacin , dihydro - streptomycin , dirithromycin , docycycline , efrotomycin , enoxacin , enrofloxacin , ertapenem , erythromycin and salts thereof , ethambutol hcl and other salts , ethionamide , florfenicol , flumequine , fosfomycin , fosfomycin , gamithromycin , gatifloxacin , gentamycin , imipenem , imipenem - cilastin , isoniazid , kanamycin , levofloxacin , lincomycin , linezolid , lomefloxacin , loracarbef mafenide , marbofloxacin , meropenem , methenamine , methicillin , metronidazole , mezlocillin , minocycline , moxifloxacin , nafcillin , nalidixic acid , neomycin , netilmicin , nitrofurantoin , norfloxacin , novobiocin , ofloxacin , orbifloxacin , ormetoprim , oxacillin , oxytetracycline , paromomycin , penicillin g , penicillin g aqueous , penicillin g benzatine , penicillin g procaine , penicillin v , penicillin v penicillin salts and complexes , pentamidine , piperacillin , piperacillin sodium , piperacillin - tazobactam , polymixin b , pyrazinamide , rifampin , roxithromycin , salts of carbenicillin , silver sulfadiazine , sparfloxacin , spectinomycin , spiramycin , streptomycin , streptozocin , sufadimethoxine - ormetoprim , sulfacetamide , sulfacytine , sulfadiazine , sulfadimethoxine , sulfadimethoxine - trimethoprim , sulfamerazine , sulfamethazine , sulfamethixole , sulfapyridine , sulfapyrizine , sulfasalazine , sulfinethoxazole , sulfisoxazole , tazobactam , teicoplanin , tetracycline , tetracycline hcl , tiamulin , ticarcillin , ticarcillin and clavulanate potassium , tilmicosin , tobramycin , trimethoprim , trimetrexate and ketolides , troleanomycin , trovafloxacin , tulathromycin , tylosin , vancomycin and ketolides such as telithromycin and hmr 3004 . 41 . the formulation according to paragraph 39 wherein the antibiotic is clindamycin or a pharmaceutically acceptable salt or hydrate thereof . 42 . the formulation according to paragraph 39 wherein the antibiotic is clindamycin phosphate . 43 . the formulation according to paragraph 39 wherein the poloxamer is selected from any available poloxamer . 44 . the formulation according to paragraph 39 wherein the poloxamer is poloxamer 407 or poloxamer 188 or a combination thereof . 45 . a process for preparing the long - acting injectable veterinary formulation according to paragraph 38 which comprises the steps of : ( a ) stirring the poloxamer into purified water at 5 ° c . ; ( b ) optionally adding a second poloxamer to the mixture from step ( a ) and mixing the mixture ; and ( c ) optionally adding a polyacrylic acid into an aliquot of water , and completely hydrating the polyacrylic acid before mixing it into the poloxamer solution at 5 ° c . ; ( d ) neutralizing the carbopol using triethanolamine . ( e ) dissolving the drug in ethanol / propylene glycol and adding it to the above solution . 46 . a process for preparing the long - acting injectable veterinary formulation according to paragraph 38 which comprises the steps of : ( a ) dissolving poloxamer 407 completely in water at room temperature or water pre - cooled to approximately 5 ° c . ; ( b ) dissolving active substances that are insoluble in water , in ethanol , isopropanol or propylene glycol ; and ( c ) mixing the therapeutic agent solution with the aqueous phase at 5 ° c . to form a homogeneous mass . 47 . a process for preparing the long - acting injectable veterinary formulation according to paragraph 38 which comprises the steps of : ( a ) dissolving poloxamer 407 in water at room temperature at approximately 70 ° c . ; ( b ) dissolving active substances that are insoluble in water , in ethanol , isopropanol or propylene glycol at 70 ° c . ; and ( c ) mixing the therapeutic agent solution with the warm aqueous phase to form a homogeneous mass . 48 . a method for treating a bacterial infection in an animal comprising administering to the animal any one of the formulations of paragraphs 38 through 44 . 49 . the method of paragraph 22 wherein the animal receives treatment on any of days 0 , 7 , 14 , 21 , and 28 comprising administering any of the formulations of paragraphs 38 through 44 , wherein the formulation provides sustained concentrations of therapeutic agents for 7 - 10 days . having thus described in detail preferred embodiments of the present invention , it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention .
this document relates to formulations for combating bacterial infections in animals which provide for improved long - acting oral and injectable formulations for systemic delivery of antibiotics , which are designed to achieve high bioavailability .